{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:51:55Z","timestamp":1792266715530,"version":"4.4.0"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jdcr.2026.06.055","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:42:22Z","timestamp":1782862942000},"page":"170-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Refractory verrucous psoriasis achieving clearance with guselkumab and subsequent response to excimer therapy"],"prefix":"10.1016","volume":"75","author":[{"given":"Luke C.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clay","family":"Cockerell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5788-7445","authenticated-orcid":false,"given":"Angela Yen","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdcr.2026.06.055_bib1","first-page":"672","article-title":"Verrucous psoriasis: an integrative review of pathogenesis, diagnosis, and treatment landscape","volume":"15","author":"Guo","year":"2024","journal-title":"J Clin Exp Dermatol Res"},{"issue":"8","key":"10.1016\/j.jdcr.2026.06.055_bib2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.36849\/JDD.6626","article-title":"Pediatric verrucous psoriasis: a case report in a pediatric patient and discussion of the literature","volume":"21","author":"Sherkin","year":"2022","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2026.06.055_bib3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00403-025-04085-2","article-title":"Verrucous psoriasis and current treatments: a review of the literature","volume":"317","author":"Rahman","year":"2025","journal-title":"Arch Dermatol Res"},{"issue":"9","key":"10.1016\/j.jdcr.2026.06.055_bib4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/jamadermatol.2025.1836","article-title":"Guselkumab for moderate to severe psoriasis across all skin tones: cohort A of the VISIBLE randomized clinical trial","volume":"161","author":"Alexis","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2026.06.055_bib5","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jdcr.2026.06.055_bib6","article-title":"Case report: successful treatment of guselkumab in a patient with verrucous psoriasis unresponsive to secukinumab","volume":"16","author":"Zheng","year":"2025","journal-title":"Front Immunol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626004030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626004030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:37:54Z","timestamp":1792265874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626004030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":6,"alternative-id":["S2352512626004030"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.06.055","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refractory verrucous psoriasis achieving clearance with guselkumab and subsequent response to excimer therapy","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.06.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}